Adaptive Biotechnologies (ADPT) Cash from Investing Activities (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash from Investing Activities across 9 years of filings, most recently posting $9.1 million for Q1 2026.

• Cash from Investing Activities for Q1 2026 came in at $9.1 million, down 64.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.5 million (down 63.44% YoY), and the FY2025 annual result was $37.9 million, down 51.22% from the prior year.
• Cash from Investing Activities came in at $9.1 million for Q1 2026 at Adaptive Biotechnologies, up from -$8.3 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $63.0 million in Q1 2023 to a low of -$97.5 million in Q4 2022.
• The 5-year median for Cash from Investing Activities is $17.3 million (2025), against an average of $15.1 million.
• Across the five-year window, Cash from Investing Activities sank 245.13% in 2022 and jumped 686.41% in 2023, its largest moves.
• Adaptive Biotechnologies' Cash from Investing Activities stood at -$97.5 million in 2022, then jumped by 103.29% to $3.2 million in 2023, then soared by 589.71% to $22.1 million in 2024, then slumped by 137.31% to -$8.3 million in 2025, then soared by 210.8% to $9.1 million in 2026.
• The last three Cash from Investing Activities figures came in at $9.1 million (Q1 2026), -$8.3 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.